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Heart disease is a leading cause of death in adults and children. We, and others,
have described complex signaling, transcriptional, and translational networks
that guide early differentiation of cardiac progenitors and later morphogenetic
events during cardiogenesis. We found that networks of transcription factors and
miRNAs function through intersecting positive and negative feedback loops to
reinforce differentiation and proliferation decisions. We have utilized a combi-
nation of major cardiac regulatory factors to induce direct reprogramming of
cardiac fibroblasts into cardiomyocyte-like cells with global gene expression and
electrical activity similar to cardiomyocytes. The in vivo efficiency of
reprogramming into cells that are more fully reprogrammed was greater than
in vitro and resulted in improved cardiac function after injury. We have also
identified a unique cocktail of transcription factors and small molecules that
reprogram human fibroblasts into cardiomyocyte-like cells and are testing these
in large animals. Knowledge regarding the early steps of cardiac differentiation
in vivo has led to effective strategies to generate necessary cardiac cell types for
regenerative approaches and may lead to new strategies for human heart disease.
Keywords
Cardiac • Reprogramming • Regeneration • Transcription factors
D. Srivastava (*)
Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA
Department of Pediatrics and Department of Biochemistry and Biophysics, University of
California, San Francisco, San Francisco, CA 94158, USA
e-mail: dsrivastava@gladstone.ucsf.edu
# The Author(s) 2016




Heart disease remains the leading cause of death worldwide, despite improved
treatments that have decreased death rates from cardiovascular diseases. Congenital
heart malformations, the most common of all human birth defects, occur in nearly
1 % of the population worldwide, regardless of race. With more than one million
survivors of congenital heart disease (CHD) in the United States, it is becoming
apparent that genetic disruptions that predispose to developmental defects can have
ongoing consequences in maintenance of specific cell types and cellular processes
over decades. A more precise understanding of the causes of CHD is imperative for
the recognition and potential intervention of progressive degenerative conditions
among survivors of CHD.
Because cardiomyocytes (CMs) rarely regenerate in postnatal hearts, survivors
of congenital and acquired heart disease often develop chronic heart failure.
Unfortunately, end-stage heart failure can only be addressed by heart transplanta-
tion, which is limited by the number of donor organs available, particularly in
children. Alternative solutions include cellular therapy that replaces lost CMs either
by transplanting CMs or inducing new CMs in situ at areas affected by the
infarction.
In recent years it has become apparent that adult somatic cells can be converted
into other types of cells through epigenetic reprogramming. With this technology,
for example, somatic cells, such as fibroblasts, can be dedifferentiated into pluripo-
tent stem cells by nuclear transfer [1] or with defined transcription factors [2]. Direct
reprogramming of fibroblasts into the chief functional cells of different organs,
including CMs, neurons, hepatocytes, hematopoietic cells, and endothelial cells,
has been accomplished and holds great promise for regenerative medicine [3]. In
particular, cardiac fibroblasts represent a large pool of cells in the adult heart [4] and
thus may provide a reservoir of cells from which to generate new CMs through
epigenetic reprogramming.
In 2010, we reported that mouse cardiac and dermal fibroblasts could be directly
reprogrammed into induced CM-like cells (iCMs) in vitro by a combination of three
developmental cardiac transcription factors, Gata4, Mef2c, and Tbx5 (GMT)
[5]. Since then, other labs around the world have reported success in
reprogramming mouse fibroblasts into iCMs with similar cocktails of
reprogramming factors [6–10]. We and others have also directly converted
human cardiac and dermal fibroblasts into cardiac cells [11–13]. Several review
papers published from different labs illustrate the potential and challenges of this
new avenue for cardiac regenerative medicine [14–19].
Here, we discuss the cardiac developmental biology discoveries that underpin
direct reprogramming approaches and consider the opportunities and challenges of
this technology for addressing cardiac regeneration.
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1.2 Molecular Networks Regulate Cardiac Cell Fate
In vertebrate embryos, the heart is the first functional organ to form. The morphologi-
cal development of the heart has been summarized in several reviews. During devel-
opment, numerous signaling and transcriptional cascades regulate cell fate decisions
in distinct heart fields. In addition, the Gata, Mef2, Hand, Nkx, and T-box family of
transcription factors control expression of cardiac genes and direct the specification
and differentiation of cardiac myocytes. These transcription factors have been fre-
quently included in studies that directly convert fibroblasts into cardiac cells.
MicroRNAs (miRs)—small single-stranded noncoding RNAs that negatively
regulate the stability of gene transcripts—also regulate cardiac gene expression
[20, 21]. Transcription factors regulate miR expression, and in turn, miRs can
modulate the activities of transcription factors through positive and negative feed-
back loops. One of the major regulators of cardiac lineage determination during
heart development is miR-1. Expression of miR-1 in either mouse or human
embryonic stem cells (ESCs) caused them to favor the muscle cell fate. In contrast,
miR-133 promoted muscle progenitor expansion and prevented terminal differenti-
ation, while another miRNA, miR-499, promoted the ventricular cell fate in human
ESC-differentiated CMs and caused cardiac hypertrophy and enlarged hearts in
miR-499 transgenic mice. These studies demonstrate that miRs cooperate with
transcription factors to form an intertwined network that reinforces specific cell
fate decisions and differentiation during cardiac development.
1.3 Cardiac Fibroblasts in the Normal and Remodeling Heart
Fibroblasts are mesenchymal cells that produce many extracellular matrix
components in organs. Fibroblasts show heterogeneity based on morphology,
glycogen pools, collagen production, cell surface markers, and global gene-
expression profiles. Although the percentage of fibroblasts among the total cells
in the heart varies between species, the large population of fibroblasts is quiescent
and abundantly distributed in the interstitial and perivascular matrix in the normal
heart.
Cardiac fibroblasts synthesize extracellular matrix to provide a 3D network for
myocytes and other cells of the heart; they also regulate the biological and electro-
physiological response of CMs during physiological and pathological development.
In embryonic mouse hearts, cardiac fibroblasts induced proliferation of CMs via
paracrine signals of fibronectin, collagen, and heparin-binding EGF-like growth
factor; however, in adult mouse hearts, cardiac fibroblasts promoted hypertrophic
maturation of CMs via beta1-integrin signaling [22]. Cardiac fibroblasts were also
found to form intracellular electrical coupling and communicate with myocytes
through gap junctions, suggesting that cardiac fibroblasts could conduct electric
signaling between different regions of myocytes that are electrically isolated by
connective tissue in the normal heart.
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1.4 Direct Cardiac Reprogramming In Vitro
To identify the combination of reprogramming factors that could convert a cardiac
fibroblast toward a cardiomyocyte-like state, we generated a transgenic mouse in
which enhanced green fluorescent protein (EGFP) was driven by the alpha myosin
heavy chain (αMHC) promoter [5, 22], providing a tool to screen through many
potential regulators. We ultimately found that a combination of three transcription
factors—Gata4, Mef2c, and Tbx5 (GMT)—could convert ~15 % of cardiac
fibroblasts into αMHC-EGFP-positive cells, which we called induced CM-like
cells (iCMs) [5]. iCMs formed sarcomere structures and displayed whole-
transcriptome expression profiles that were shifted significantly toward the profile
of CMs, even at the single-cell level. Although most in vitro iCMs were only
partially reprogrammed, many of them could generate Ca2+ transients, and some
started beating spontaneously 4–6 weeks after reprogramming. Using a lineage-
tracing strategy in mice (e.g., Isl1-Cre-YFP and Mesp1-Cre-YFP), we did not
observe activation of cardiac progenitor markers during GMT cardiac
reprogramming [5], suggesting that GMT directly converted fibroblasts toward
the cardiac cell fate without dedifferentiation back into a progenitor status. Song
et al. [8] found that a basic helix-loop-helix transcription factor, Hand2, could help
GMT to convert TTFs into functional beating iCMs.
1.5 Direct Cardiac Reprogramming In Vivo
The ultimate goal in generating new iCMs is to improve systolic function of
damaged hearts and restore its normal structure and function. Therefore, we tested
direct cardiac reprogramming in vivo with the hypothesis that the heart’s native
microenvironment would promote direct reprogramming of fibroblasts to CMs. We
expected that direct cardiac reprogramming would be enhanced in the native heart
and could improve the function of the damaged heart.
We delivered GMT into mouse hearts after acute MI via retroviruses. These
viruses can only infect actively dividing cells and, thus, could deliver the
reprogramming factors into non-myocytes (mostly fibroblasts), but not into CMs
that exit the cell cycle after differentiation. Four weeks after introducing GMT, we
found numerous genetically labeled reprogrammed cells within the scar area of
mouse hearts, indicating newly born iCMs reprogrammed from cardiac fibroblasts
(Fig. 1.1). We found that more than 50 % of in vivo-derived iCMs closely
resembled endogenous ventricular CMs, had a rod shape, were binucleate, assem-
bled sarcomeres, generated Ca2+ transients, and elicited ventricular-like action
potentials and beating activity [23]. By microarray analysis, in vivo mouse
GMT-iCMs showed similar global gene-expression profiles with mouse adult
CMs, such that they were clustered as one type of cells [11]. The iCMs
reprogrammed in vivo were electrically coupled with endogenous CMs, and no
arrhythmias were observed in mice that received GMT reprogramming factors.
Most importantly, introducing GMT in vivo reduced scar size and cardiac
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dysfunction up to 12 weeks after coronary ligation [23]. Similarly, Inagawa
et al. [24] successfully reprogrammed cardiac fibroblasts into iCMs in vivo by
introducing GMT into the heart of immunosuppressed mice with single-
polycistronic retrovirus, which contains GMT with self-cleaving 2A peptides.
Furthermore, Song et al. [8] found that introducing GMT and Hand2 in vivo
could directly convert cardiac fibroblasts into iCMs and also improved function
and decreased scar.
1.6 Direct Cardiac Reprogramming in Human Fibroblasts
Establishing the technology of cardiac reprogramming in human cells was a
necessary step toward considering clinical application. However, neither GMT
nor GHMT, which reprogrammed iCMs from mouse fibroblasts, was able to
reprogram human fibroblasts into iCMs in vitro [11–13]; however, inclusion of
additional reprogramming factors resulted in successful reprogramming. Nam
et al. [12] found that GHT, without MEF2C, but with another transcription factor,
myocardin, and two muscle-specific miRNAs, miR-1 and miR-133, could repro-
gram human fibroblasts into iCMs. These reprogrammed iCMs expressed multiple
cardiac genes, developed sarcomere-like structures, and generated Ca2+ transients
with a small subset of the cells exhibiting spontaneous contractility after 11 weeks
in culture. Wada R. et al. [13] reported that GMT with MESP1 and myocardin could
activate cardiac gene expression in human neonatal and adult cardiac fibroblasts. In
our study, pairing GMT with ESRRG and MESP1 induced global expression of
cardiac genes and shifted the phenotype of human fibroblasts toward the CM-like
state. Reprogrammed human iCMs were epigenetically stable and formed sarco-
mere structures, and some could generate Ca2+ transients and action potentials
[11]. By comparing whole-transcriptome expression of 4-week and 12-week
iCMs, we found that reprogramming human cells takes longer than mouse cells
because of their progressive repression of fibroblast genes. Nonetheless, our analy-


















Fig. 1.1 In situ reprogramming of fibroblasts to cardiomyocytes. Representative histologic
sections from mouse hearts treated with dsRed or Gata4/Mef2c/Tbx5 containing retroviral vectors
injected into the myocardium after coronary ligation. Scar area quantification is indicated
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level, human iCMs were reprogrammed at a level similar to mouse iCMs
reprogrammed by GMT in vitro [11].
1.7 Challenges and Future Directions
The studies summarized here demonstrate that forced expression of three or four
developmentally critical transcription factors can directly convert mouse cardiac
fibroblasts into CM-like cells in vitro, although most of these iCMs were partially
reprogrammed. These same factors generated more mature CM-like cells in the
native heart, improved heart function, and reduced scar size in the mouse heart post-
MI. Similarly, expression of five to seven reprogramming factors converted human
fibroblasts into non-perfect iCMs in vitro. By comparing in vitro versus in vivo
iCMs in mice [8, 23] and considering the similarities between human and mouse
iCMs in vitro [11], we speculate that the cocktails recently identified in human
fibroblasts may be sufficient to reprogram adult CM-like cells that are fully
functional in the in vivo environment, such as in the pig or nonhuman primate
heart, as is the case in mice. These studies have been driven by the deep knowledge
of cardiac development gained over the last two decades and represent a valuable
application of this knowledge for potential clinical development postnatally.
Successfully achieving cardiac reprogramming requires high expression and
proper stoichiometry of reprogramming factors, healthy and non-senescent
fibroblasts, and optimal conditions for cell culture. In addition, culture conditions,
such as electric stimulation, might help facilitate and maintain the functional
maturation of iCMs at late stages (i.e., after cardiac cell fate conversion), and the
process may require some small-molecule compounds and growth factors to over-
come epigenetic barriers at the early stages of in vitro reprogramming. The epige-
netic barriers that prevent cardiac reprogramming in vitro remain unknown;
however, the in vivo environment of the heart appears to overcome these epigenetic
blocks. We speculate that secreted factors and direct cell-cell interactions, includ-
ing mechanical and electrical, from myocytes and non-myocytes may work
together to improve direct cardiac reprogramming.
Another elusive concept is the molecular mechanism that underlies direct
cardiac reprogramming. What are the DNA targets of those reprogramming
factors? How are those transcriptional changes epigenetically stabilized during
reprogramming? By combining mechanism assays at whole-population and
single-cell levels, we can gain a more integral and comprehensive understanding
of how core transcription factors establish a self-reinforcing molecular network that
controls cardiac cell fate.
While many challenges and hurdles remain in this blossoming research field, the
high demand for regenerative medicine strategies for the heart emphasizes the
significance of these efforts in discovering new therapeutic strategies. Observing
the functional benefits of in vivo reprogramming in mouse heart and the promising
and similar degree of reprogramming in mouse and human in vitro iCMs, we are
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endeavoring to translate direct cardiac reprogramming for future clinical
applications.
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